Resumen: EP-173
Aim/Introduction: To analyze the validity of [18F]F-Choline PET-CT results in prostate cancer recurrence in our daily practice, based on theoretical cut-off points of prostatespecific antigen (PSA), its kinetic, and PSA doubling time (PSADT), to identify predictors of positivity and modify the indication criteria. Materials and
Methods: Prior to the validity analysis, a descriptive, prospective analysis of consecutive patients with prostate cancer treated with curative intent by radical prostatectomy (RP) or radiotherapy (RT), who underwent PET-CT scan with recurrence criteria: PSA =1 or PSA 0.4-1 with PSADT <6 months after RP; PSA> Nadir + 2 after RT, was performed.
Results: From April to December 2019, 69 patients were included, 40 were treated with RP (58%) and 29 with RT (42%). In 45 patients (65%) PET-CT was able to identify recurrence of the disease (positive PET) and in 24 it was not (negative PET). Of patients treated with RP, 82, 5% (33/40) had PSA>1, and of those, 61% were positive PET. 17, 5% (7/40) had PSA<1 and PSADT< 6 months (28/69), with positive PET in 43% of patients. 76% of patients had a positive PET after RT. Positive PET results were obtained in 57% of patients with PSADT>6months (28/69), in 71% if PSADT<6months (41/69) and in 81% of patients if PSADT<3 months (16/69). After RP and RT, PET was positive in 50% and 62, 5% of patients respectively if PSADT>6 months, in 61% and 92% if PSADT<6 months and in 77% and 100% if PSADT<3 months.
Conclusion: Preliminarily and awaiting validation, it seems that PSA>1 after RP or Nadir +2 after RT is an indicator of PET-CT. There seems to be a tendency that shows that PSA<1 after RP is an indicator of PET-CT if PSADT<3 months. PSADT <3 or <6 months could be the best predictor of positivity of PET-CT with [18F]F-Choline in recurrent prostate cancer. Idioma: Inglés Año: 2020 Publicado en: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 47, SUPPL 1 (2020), S593 ISSN: 1619-7070 Originalmente disponible en: Texto completo de la revista